Zoetis Inc. (NYSE:ZTS) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Wednesday.

Several other research analysts also recently commented on ZTS. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $62.00 target price on shares of Zoetis in a report on Monday, August 7th. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 target price on shares of Zoetis in a report on Wednesday, September 6th. Piper Jaffray Companies set a $73.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, August 25th. Finally, Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $65.44.

Shares of Zoetis (NYSE:ZTS) opened at 64.24 on Wednesday. Zoetis has a one year low of $46.86 and a one year high of $65.83. The company has a 50-day moving average price of $62.44 and a 200 day moving average price of $59.64. The firm has a market capitalization of $31.42 billion, a P/E ratio of 36.31 and a beta of 1.02.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.53. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. Zoetis’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 EPS. Analysts expect that Zoetis will post $2.34 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades Zoetis Inc. (ZTS) to Buy” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/22/bidaskclub-downgrades-zoetis-inc-zts-to-buy.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Zoetis by 3.9% in the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after purchasing an additional 1,412,829 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after acquiring an additional 910,265 shares in the last quarter. State Street Corp boosted its position in shares of Zoetis by 4.9% during the 1st quarter. State Street Corp now owns 21,256,557 shares of the company’s stock valued at $1,134,453,000 after acquiring an additional 986,680 shares in the last quarter. Morgan Stanley boosted its position in shares of Zoetis by 182.5% during the 1st quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after acquiring an additional 9,442,207 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Zoetis by 55.4% during the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after acquiring an additional 3,695,449 shares in the last quarter. Institutional investors own 93.20% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.